Zoetis Dermatology — Revenue decreased by 18.6% to $349.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 10.5%, from $390.00M to $349.00M. Over 4 years (FY 2021 to FY 2025), Dermatology — Revenue shows an upward trend with a 10.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates strong demand for specialized pet health treatments and successful product adoption, while a decrease may signal increased competition or a slowdown in veterinary clinic visits for dermatological issues.
This metric represents the total gross sales generated from the company's portfolio of animal dermatology products, incl...
Comparable to specialized therapeutic segment revenues at other animal health or pharmaceutical companies, often benchmarked against broader companion animal health growth rates.
zts_segment_dermatology_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $285.00M | $326.00M | $321.00M | $311.00M | $319.00M | $348.00M | $351.00M | $292.00M | $359.00M | $397.00M | $379.00M | $363.00M | $418.00M | $453.00M | $421.00M | $390.00M | $463.00M | $472.00M | $429.00M | $349.00M |
| QoQ Change | — | +14.4% | -1.5% | -3.1% | +2.6% | +9.1% | +0.9% | -16.8% | +22.9% | +10.6% | -4.5% | -4.2% | +15.2% | +8.4% | -7.1% | -7.4% | +18.7% | +1.9% | -9.1% | -18.6% |
| YoY Change | — | — | — | — | +11.9% | +6.7% | +9.3% | -6.1% | +12.5% | +14.1% | +8.0% | +24.3% | +16.4% | +14.1% | +11.1% | +7.4% | +10.8% | +4.2% | +1.9% | -10.5% |